Treatment with biologic DMARDs may not adversely
affect lung nodules in rheumatoid arthritis patients

AVANOĞLU GÜLER, Aslıhan; ATAŞ, Nur; SATİŞ, Hasan; öztürk, mehmet akif; HAZNEDAROĞLU, Şeminur; TUFAN, Abdurrahman; Goker, Berna; BİLİCİ SALMAN, Reyhan; BABAOĞLU, Hakan; CİNDİL, Emetullah; KARADENİZ, HAZAN

doi:10.5152/eujrheum.2022.21067

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients

Hazan Karadeniz, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Emetullah Cindil, (Radyoloji Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Hakan Babaoğlu, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Aslıhan Avanoğlu Güler, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Reyhan Bilici Salman, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Hasan Satiş, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Nur Ataş, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Berna Göker, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Şeminur Haznedaroğlu, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Mehmet Akif Öztürk, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Abdurrahman Tufan, (Romatoloji Anabilim Dalı, Anabilim Dalı İç Hastalıkları Anabilim Dalı, Gazi Üniversitesi Tıp Fakültesi, Ankara, Türkiye)

Diğer Yazarlar

European Journal of Rheumatology

4 0

Yıl: 2022 Cilt: 9 Sayı: 2 Sayfa Aralığı: 75 - 81 Metin Dili: İngilizce DOI: 10.5152/eujrheum.2022.21067 İndeks Tarihi: 24-06-2022

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients

Öz:

Objective: Lung nodules (LNs) impose diagnostic and therapeutic challenges in patients with rheuma- toid arthritis (RA) due to unpredictable outcomes. Potential induction of nodulosis with the use of con- ventional synthetic DMARDs (csDMARD) and lack of knowledge regarding the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs)/tofacitinib on the LN raise concerns and have an impact on treatment decisions. This study aims to evaluate the possible effects of the bDMARDs/tofa- citinib and csDMARDS on LNs observed in RA patients. Methods: Electronic health records of RA patients who had LNs detected on computed tomography (CT) between January 2015 and December 2020 were evaluated retrospectively. Patients with follow- up CT images were included in the study. Baseline and follow-up images were meticulously examined for the number, size, attenuation, and cavity formation. Clinical, histopathologic, and laboratory find- ings were analyzed. Results: Forty-two RA patients with LNs were studied, 21 were on bDMARDs/tofacitinib (11 females, mean age: 59.7 6 8.4) and 21 were on csDMARDs (12 females, mean age: 71.4 6 8.3). The proportion of patients with progressed nodules during follow-up was comparable between groups (six patients in bDMARDs/tofacitinib vs seven patients in csDMARDs). Progression of LNs was observed in six patients in the bDMARDs/tofacitinib group: three in anti-TNFa, two in rituximab, and one in abatacept users and none in tofacitinib users. Conclusion: Our results suggest that the risk of progression in LNs in RA patients with use of bDMARDs/tofacitinib might not impose a higher risk compared to csDMARDs. Moreover, bDMARDs/ tofacitinib might result in regression in LNs

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4(5):443-448. [CrossRef]
2. Chansakul T, Dellaripa PF, Doyle TJ, Madan R. Intra-thoracic rheumatoid arthritis: Imaging spectrum of typical findings and treatment related complications. Eur J Radiol. 2015;84(10):1981-1991. [CrossRef]
3. Sargin G, Senturk T. Multiple pulmonary rheu- matoid nodules. Reumatologia. 2015;5 (5):276- 278. [CrossRef]
4. Patterson JW. Rheumatoid nodule and subcu- taneous granuloma annulare. A comparative histologic study. Am J Dermatopathol. 1988;10(1):1-8. [CrossRef]
5. Wikaningrum R, Highton J, Parker A, et al. Path- ogenic mechanisms in the rheumatoid nodule: Comparison of proinflammatory cytokine pro- duction and cell adhesion molecule expression in rheumatoid nodules and synovial mem- branes from the same patient. Arthritis Rheum. 1998;41(10):1783-1797. [CrossRef]
6. Sagdeo P, Gattimallanahali Y, Kakade G, Canchi B. Rheumatoid lung nodule. BMJ Case Rep. 2015;2015:bcr2015213083.
7. Glace B, Gottenberg JE, Mariette X, et al. Effi- cacy of rituximab in the treatment of pulmo- nary rheumatoid nodules: Findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/ PR registry). Ann Rheum Dis. 2012;71(8):1429- 1431. [CrossRef]
8. Akiyama M, Mawatari T, Nakashima Y, et al. Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment. Clin Rheumatol. 2015;34(11):1867-1875. [CrossRef]
9. Alpert JB, Ko JP. Management of incidental lung nodules: Current strategy and rationale. Radiol Clin N Am. 2018;56(3):339-351.
10. Somarouthu B, Lee SI, Urban T, Sadow CA, Harris GJ, Kambadakone A. Immune-related tumour response assessment criteria: A com- prehensive review. Br J Radiol. 2018;91(1084):20170457. [CrossRef]
11. Liote ́ H. Pulmonary manifestation of rheuma- toid arthritis. Rev Mal Respir. 2008; 25:973-988. [CrossRef]
12. Truong MT, Ko JP, Rossi SE, et al. Update in the evaluation of the solitary pulmonary nodule. Radiographics. 2014;34(6):1658-1679. [Cross- Ref]
13. Attar SM. Adverse effects of low dose metho- trexate in rheumatoid arthritis patients. A hospital-based study. Saudi Med J. 2010;31(8):909-915.
14. Makihara S, Kariya S, Noujima-Harada M, et al. Methotrexate-associated lymphoproliferative disorder with multiple pulmonary nodules and bilateral cervical lymphadenopathy. Auris Nasus Larynx. 2019;46(6):927-933. [CrossRef]
15. Kim SH, Yoo WH. Recurrent pneumothorax associated with pulmonary nodules after leflu- nomide therapy in rheumatoid arthritis: A case report and review of the literature. Rheumatol Int. 2011;31(7):919-922. [CrossRef]
16. Atzeni F, Boiardi L, Sallı` S, Benucci M, Sarzi-Put- tini P. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol. 2013;9(7):649- 657. [CrossRef]
17. Gauhar UA, Gaffo AL, Alarco ́ n GS. Pulmonary manifestations of rheumatoid arthritis. Semin Respir Crit Care Med. 2007;28(4):430-440. [CrossRef]
18. Toussirot E, Berthelot JM, Pertuiset E, et al. Pul- monary nodulosis and aseptic granulomatous lung disease occurring in patients with rheu- matoid arthritis receiving tumor necrosis factor-alpha-blocking agent: A case series. J Rheumatol. 2009;36(11):2421-2427. [Cross- Ref]
19. Watson P, Simler N, Screaton N, Lillicrap M. Management of accelerated pulmonary nodu- losis following etanercept therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2008;47(6):928-929. [CrossRef]
20. Braun MG, Wagener P. Regression of peripheral and pulmonary rheumatoid nodules under therapy with rituximab. Z Rheumatol. 2013;72(2):166-171. [CrossRef]
21. Andres M, Vela P, Romera C. Marked improve- ment of lung rheumatoid nodules after treat- ment with tocilizumab. Rheumatology (Oxford). 2012;51(6):1132-1134. [CrossRef]

APA	KARADENİZ H, CİNDİL E, BABAOĞLU H, AVANOĞLU GÜLER A, BİLİCİ SALMAN R, SATİŞ H, ATAŞ N, Goker B, HAZNEDAROĞLU Ş, öztürk m, TUFAN A (2022). Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. , 75 - 81. 10.5152/eujrheum.2022.21067
Chicago	KARADENİZ HAZAN,CİNDİL Emetullah,BABAOĞLU Hakan,AVANOĞLU GÜLER Aslıhan,BİLİCİ SALMAN Reyhan,SATİŞ Hasan,ATAŞ Nur,Goker Berna,HAZNEDAROĞLU Şeminur,öztürk mehmet akif,TUFAN Abdurrahman Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. (2022): 75 - 81. 10.5152/eujrheum.2022.21067
MLA	KARADENİZ HAZAN,CİNDİL Emetullah,BABAOĞLU Hakan,AVANOĞLU GÜLER Aslıhan,BİLİCİ SALMAN Reyhan,SATİŞ Hasan,ATAŞ Nur,Goker Berna,HAZNEDAROĞLU Şeminur,öztürk mehmet akif,TUFAN Abdurrahman Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. , 2022, ss.75 - 81. 10.5152/eujrheum.2022.21067
AMA	KARADENİZ H,CİNDİL E,BABAOĞLU H,AVANOĞLU GÜLER A,BİLİCİ SALMAN R,SATİŞ H,ATAŞ N,Goker B,HAZNEDAROĞLU Ş,öztürk m,TUFAN A Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. . 2022; 75 - 81. 10.5152/eujrheum.2022.21067
Vancouver	KARADENİZ H,CİNDİL E,BABAOĞLU H,AVANOĞLU GÜLER A,BİLİCİ SALMAN R,SATİŞ H,ATAŞ N,Goker B,HAZNEDAROĞLU Ş,öztürk m,TUFAN A Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. . 2022; 75 - 81. 10.5152/eujrheum.2022.21067
IEEE	KARADENİZ H,CİNDİL E,BABAOĞLU H,AVANOĞLU GÜLER A,BİLİCİ SALMAN R,SATİŞ H,ATAŞ N,Goker B,HAZNEDAROĞLU Ş,öztürk m,TUFAN A "Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients." , ss.75 - 81, 2022. 10.5152/eujrheum.2022.21067
ISNAD	KARADENİZ, HAZAN vd. "Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients". (2022), 75-81. https://doi.org/10.5152/eujrheum.2022.21067

APA	KARADENİZ H, CİNDİL E, BABAOĞLU H, AVANOĞLU GÜLER A, BİLİCİ SALMAN R, SATİŞ H, ATAŞ N, Goker B, HAZNEDAROĞLU Ş, öztürk m, TUFAN A (2022). Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. European Journal of Rheumatology, 9(2), 75 - 81. 10.5152/eujrheum.2022.21067
Chicago	KARADENİZ HAZAN,CİNDİL Emetullah,BABAOĞLU Hakan,AVANOĞLU GÜLER Aslıhan,BİLİCİ SALMAN Reyhan,SATİŞ Hasan,ATAŞ Nur,Goker Berna,HAZNEDAROĞLU Şeminur,öztürk mehmet akif,TUFAN Abdurrahman Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. European Journal of Rheumatology 9, no.2 (2022): 75 - 81. 10.5152/eujrheum.2022.21067
MLA	KARADENİZ HAZAN,CİNDİL Emetullah,BABAOĞLU Hakan,AVANOĞLU GÜLER Aslıhan,BİLİCİ SALMAN Reyhan,SATİŞ Hasan,ATAŞ Nur,Goker Berna,HAZNEDAROĞLU Şeminur,öztürk mehmet akif,TUFAN Abdurrahman Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. European Journal of Rheumatology, vol.9, no.2, 2022, ss.75 - 81. 10.5152/eujrheum.2022.21067
AMA	KARADENİZ H,CİNDİL E,BABAOĞLU H,AVANOĞLU GÜLER A,BİLİCİ SALMAN R,SATİŞ H,ATAŞ N,Goker B,HAZNEDAROĞLU Ş,öztürk m,TUFAN A Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. European Journal of Rheumatology. 2022; 9(2): 75 - 81. 10.5152/eujrheum.2022.21067
Vancouver	KARADENİZ H,CİNDİL E,BABAOĞLU H,AVANOĞLU GÜLER A,BİLİCİ SALMAN R,SATİŞ H,ATAŞ N,Goker B,HAZNEDAROĞLU Ş,öztürk m,TUFAN A Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. European Journal of Rheumatology. 2022; 9(2): 75 - 81. 10.5152/eujrheum.2022.21067
IEEE	KARADENİZ H,CİNDİL E,BABAOĞLU H,AVANOĞLU GÜLER A,BİLİCİ SALMAN R,SATİŞ H,ATAŞ N,Goker B,HAZNEDAROĞLU Ş,öztürk m,TUFAN A "Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients." European Journal of Rheumatology, 9, ss.75 - 81, 2022. 10.5152/eujrheum.2022.21067
ISNAD	KARADENİZ, HAZAN vd. "Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients". European Journal of Rheumatology 9/2 (2022), 75-81. https://doi.org/10.5152/eujrheum.2022.21067